BRPI0411526A - vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos - Google Patents

vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos

Info

Publication number
BRPI0411526A
BRPI0411526A BRPI0411526-0A BRPI0411526A BRPI0411526A BR PI0411526 A BRPI0411526 A BR PI0411526A BR PI0411526 A BRPI0411526 A BR PI0411526A BR PI0411526 A BRPI0411526 A BR PI0411526A
Authority
BR
Brazil
Prior art keywords
tissues
microorganisms
products
methods
accumulate
Prior art date
Application number
BRPI0411526-0A
Other languages
English (en)
Inventor
Aladar A Szalay
Tatyana Timiryasova
Young A Yu
Qian Zhang
Original Assignee
Genelux Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03013826A external-priority patent/EP1489164A1/en
Priority claimed from EP03018478A external-priority patent/EP1512746B1/en
Priority claimed from EP03024283A external-priority patent/EP1526185B1/en
Application filed by Genelux Corp filed Critical Genelux Corp
Publication of BRPI0411526A publication Critical patent/BRPI0411526A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Abstract

"VìRUS DE VACCINIA E OUTROS MICRORGANISMOS RECOMBINANTES MODIFICADOS E USOS DOS MESMOS". São descritos vírus de vaccinia recombinantes úteis como um veículo de administração específico para tumor para terapia e vacinação de gene de câncer. São portanto providos métodos e microrganismos terapêuticos. Os microrganismos são projetados para se acumular em tecidos e células imunoprivilegiados, tais como em tumores e outros tecidos proliferantes e em tecidos inflamados, em comparação a outros tecidos, células e órgãos, de forma a que eles apresentem toxicidade relativamente baixa para o organismo hospedeiro. Os microrganismos são também projetados ou modificados para resultar em membranas de células porosas nas quais eles se acumulam, resultando na produção de anticorpos reativos contra proteínas e outros produtos celulares e também permitindo a exploração de tecidos proliferantes, em particular tumores, para a produção de proteínas selecionadas ou outros produtos. São providos métodos para produção de anticorpos específicos para tumores e também métodos para produção de produtos de genes codificados pelo microrganismo, bem como anticorpos reativos com o mesmo.
BRPI0411526-0A 2003-06-18 2004-06-18 vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos BRPI0411526A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03013826A EP1489164A1 (en) 2003-06-18 2003-06-18 Recombinant vaccinia viruses with modified F3 genes, uses thereof
EP03018478A EP1512746B1 (en) 2003-08-14 2003-08-14 Method for the production of a polypeptide, RNA or other compound in tumor tissue
EP03024283A EP1526185B1 (en) 2003-10-22 2003-10-22 Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
PCT/US2004/019866 WO2005047458A2 (en) 2003-06-18 2004-06-18 Modified recombinant vaccina viruses and other microorganisms, uses thereof

Publications (1)

Publication Number Publication Date
BRPI0411526A true BRPI0411526A (pt) 2006-08-01

Family

ID=34119412

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411526-0A BRPI0411526A (pt) 2003-06-18 2004-06-18 vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos

Country Status (14)

Country Link
US (11) US7588767B2 (pt)
EP (2) EP2028270B9 (pt)
JP (4) JP3934673B1 (pt)
CN (1) CN100562570C (pt)
AT (2) ATE420160T1 (pt)
AU (2) AU2004289953B2 (pt)
BR (1) BRPI0411526A (pt)
CA (1) CA2527225C (pt)
DE (1) DE602004018927D1 (pt)
HK (2) HK1084691A1 (pt)
MX (1) MXPA05013879A (pt)
RU (1) RU2376371C2 (pt)
SG (1) SG179291A1 (pt)
WO (1) WO2005047458A2 (pt)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109515D0 (en) * 2001-04-17 2001-06-06 Neg Micon As A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
CA2818693C (en) * 2002-08-12 2016-05-17 Jennerex, Inc. Methods and compositions concerning poxviruses and cancer
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
CN101341259B (zh) 2005-08-01 2011-12-21 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CN101351213B (zh) * 2005-09-07 2013-10-02 詹纳里克斯公司 使用表达gm-csf的痘病毒***性治疗转移性癌和/或全身散布性癌
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US20070077231A1 (en) * 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
US20070098828A1 (en) * 2005-11-01 2007-05-03 Gonzalez-Villasenor Lucia I Methods and compositions for the prevention and regression of neovascularization
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20110184387A1 (en) * 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
CA2634591A1 (en) * 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2557411T3 (es) 2006-01-05 2016-01-25 The Ohio State University Research Foundation Métodos y composiciones basados en microARN para el diagnóstico y el tratamiento de cánceres sólidos
CA2646051A1 (en) 2006-03-20 2007-09-27 Carlo M. Croce Microrna fingerprints during human megakaryocytopoiesis
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
CN101657547B (zh) 2006-07-13 2016-04-27 俄亥俄州立大学研究基金会 用于诊断和治疗结肠癌相关疾病的基于微小rna的方法和组合物
CA2663027A1 (en) 2006-09-19 2008-08-14 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CA2674895A1 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml)
KR100858913B1 (ko) * 2007-03-09 2008-09-17 한국과학기술원 부위특이적 변이에 의해 제조된 고수율의 ｌ－쓰레오닌생산균주 및 이를 이용한 ｌ－쓰레오닌의 제조방법
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
EP2150616A4 (en) 2007-05-10 2011-07-27 Univ Arizona REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY
EP2152883A4 (en) * 2007-05-10 2010-10-27 Univ Arizona RECOMBINANT BACTERIA COMPRISING VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES ENCODING ANTIGENS
EP2152862A1 (en) * 2007-05-14 2010-02-17 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
EP2559773B1 (en) 2007-06-08 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Methods for determining a hepatocellular carcinoma subtype
CN101903399B (zh) * 2007-06-08 2014-09-10 澳大利亚家禽Crc私人有限公司 梭菌毒素netb
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
AU2008282318B2 (en) 2007-07-31 2014-02-27 The Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US7807180B2 (en) * 2007-08-21 2010-10-05 University Of Massachusetts Poxvirus methods and compositions
JP5770472B2 (ja) 2007-08-22 2015-08-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ヒト急性白血病におけるｅｐｈａ７及びｅｒｋリン酸化の調節解除を誘発するための方法及び組成物
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
EP2201112A4 (en) 2007-10-26 2011-02-02 Univ Ohio State Res Found METHODS FOR IDENTIFYING INTERACTION OF THE "FRAGILE HISTIDINE TRIAD" GENE (FHIT) AND USES THEREOF
ES2567564T3 (es) * 2007-11-19 2016-04-25 Transgene Sa Vectores oncolíticos de poxvirus
AU2008328258B2 (en) * 2007-11-19 2013-09-26 Transgene Sa Poxviral oncolytic vectors
WO2009126189A1 (en) * 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
DK2268604T3 (en) * 2008-03-14 2017-03-27 Retrotope Inc CANCER THERAPIES BY USING ISOTO-SUBSTITUTED LYSIN
DK2276774T3 (en) 2008-03-14 2016-11-28 Retrotope Inc Drugs that modulate genome methylation.
WO2009134418A2 (en) * 2008-04-30 2009-11-05 Fox Chase Cancer Center Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
US8825503B2 (en) * 2008-05-15 2014-09-02 Youdocs, Llc Methods and systems for improving human health using targeted probiotics
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
WO2010002537A1 (en) * 2008-07-03 2010-01-07 Iowa State University Research Foundation, Inc. Cattle vaccines
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
ES2585242T3 (es) * 2008-09-19 2016-10-04 Etat Francais Représenté Par Le Directeur Central Du Service De Santé Des Armées Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
CA2781547A1 (en) 2009-11-23 2011-05-26 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
EP2526185A4 (en) 2010-01-22 2013-07-24 Univ Arizona BACTERIUM WITH REGULATED RFAH NUCLEIC ACID
WO2011150421A2 (en) * 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
CA2816603A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
RU2447150C1 (ru) * 2010-11-26 2012-04-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Средство для генной терапии злокачественных опухолей
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
CN102685768B (zh) 2011-03-08 2016-02-03 华为技术有限公司 心跳消息的处理方法、心跳周期的获取方法及接入网设备
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
CN102286415B (zh) * 2011-09-07 2014-03-05 天津工业生物技术研究所 琥珀酸高产菌株及其应用
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
PL3301177T3 (pl) * 2011-11-18 2020-08-24 Alnylam Pharmaceuticals, Inc. ŚRODKI RNAi, KOMPOZYCJE I SPOSOBY ICH ZASTOSOWANIA DO LECZENIA CHORÓB ZWIĄZANYCH Z TRANSTYRETYNĄ (TTR)
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8956873B2 (en) * 2012-01-13 2015-02-17 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US10076579B2 (en) 2012-01-13 2018-09-18 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US9023612B2 (en) 2012-01-13 2015-05-05 Bell Biosystems, Inc. Eukaryotic cells with artificial endosymbionts for multimodal detection
US8828681B2 (en) 2012-01-13 2014-09-09 Bell Biosystems, Inc. Host cells with artificial endosymbionts
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
WO2013133887A1 (en) * 2012-03-08 2013-09-12 Trimed, Incorporated System and method for treating a fractured bone
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
RU2650805C2 (ru) * 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
WO2014145785A1 (en) 2013-03-15 2014-09-18 Bell Biosystems, Llc Host cells with artificial endosymbionts
CN103589656A (zh) * 2013-05-28 2014-02-19 湖北省农业科学院畜牧兽医研究所 猪传染性胸膜肺炎放线杆菌血清1型锌离子结合蛋白a缺失株及其构建方法和应用
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
GB201310917D0 (en) * 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy
US9481869B2 (en) 2013-09-03 2016-11-01 Bell Biosystems, Inc. Host cell modification with artificial endosymbionts
US20150064759A1 (en) * 2013-09-05 2015-03-05 Braskem S.A. Modified microorganism and methods of using same for producing 2-propanol and1-propanol and/or 1,2-propanediol
US10028649B2 (en) 2013-12-02 2018-07-24 Welch Allyn, Inc. Digital colposcope system
CN104694541A (zh) * 2013-12-09 2015-06-10 江苏命码生物科技有限公司 禽流感病毒miRNA及其鉴定、检测和应用
US10711311B2 (en) * 2013-12-30 2020-07-14 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Genomic rearrangements associated with prostate cancer and methods of using the same
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN103743903A (zh) * 2014-01-08 2014-04-23 江苏省苏北人民医院 肝癌术后复发预测标志物Capn4检测方法及试剂盒
US11060149B2 (en) 2014-06-18 2021-07-13 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
JP2017522022A (ja) * 2014-07-15 2017-08-10 ベル・バイオシステムズ，インコーポレーテッド マルチモーダル検出のための人工内部共生体を含む真核細胞
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105586319B (zh) * 2014-10-20 2021-01-08 中国疾病预防控制中心性病艾滋病预防控制中心 复制型痘苗病毒载体艾滋病疫苗
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
CA2971791A1 (en) 2014-12-22 2016-06-30 Veterinaerinstituttet Salmon gill poxvirus
WO2016114638A1 (ko) * 2015-01-18 2016-07-21 엘지전자 주식회사 방송 신호 송신 장치, 방송 신호 수신 장치, 방송 신호 송신 방법, 및 방송 신호 수신 방법
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR101835180B1 (ko) 2015-03-18 2018-03-06 아주대학교산학협력단 재조합 BTG2(B cell translocation gene 2) 단백질 및 이의 생산방법
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
MX2018001755A (es) * 2015-08-11 2018-08-01 Stemimmune Incorporated Vacuna contra viruela para tratamiento del cancer.
US20200208173A1 (en) * 2015-10-30 2020-07-02 Seracare Life Sciences, Inc. Adenovirus control virus
EP3389481A4 (en) 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
CN106978397A (zh) * 2016-01-18 2017-07-25 上海宇研生物技术有限公司 一种人dc-cik免疫活性细胞及其制备方法
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center RECOMBINANT MVA OR MVADELE3L EXPRESSING FLT3L HUMAN AND THEIR USE AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
BR112018016949A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
EP3436065B1 (en) 2016-03-28 2022-04-13 Suzhou Prajna Biotech Co., Ltd. Anti-cancer oncolytic virus combination therapies and elite responder selection platforms
KR20230051601A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
HRP20211145T1 (hr) 2016-05-30 2021-12-24 Astellas Pharma Inc. Novi genetski modificiran virus vakcinije
US11452770B2 (en) 2016-07-21 2022-09-27 Kolon Life Science, Inc. Recombinant vaccinia virus and use thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
RU2757002C2 (ru) * 2016-08-09 2021-10-08 Сити Оф Хоуп Композиции химерного поксвируса и их применение
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110300801B (zh) * 2016-11-24 2023-12-08 上海凯赛生物技术股份有限公司 酸脱羧酶的蛋白与蛋白相互作用的控制
EP3550976A4 (en) 2016-12-07 2020-06-10 MD Biosciences, Inc. METHOD FOR SYNERGISTIC TREATMENT OF CANCER
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
RU2658606C1 (ru) * 2017-01-26 2018-06-21 Рашит Накипович Кадыров Штамм streptococcus pyogenes n b-7612, продуцент комплекса биологически активных соединений, обладающих иммуностимулирующими свойствами
WO2018148462A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
US20190134105A1 (en) * 2017-11-09 2019-05-09 Richard Postrel Method for Precise Identification, Targeting and Delivery of Directed Therapies with the Use of Bacteria for the Destruction of Cancerous Cells
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
AU2018236224B2 (en) 2017-03-16 2024-01-04 Alpine Immune Sciences, Inc. PD-L1 variant immunomodulatory proteins and uses thereof
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US10851350B1 (en) 2017-06-27 2020-12-01 Genelux Corporation Bioreactor production of virus from adherent cells
CN107164338A (zh) * 2017-06-27 2017-09-15 镇江市卫克生物科技有限公司 一种重组溶瘤病毒及其应用
JP2020536552A (ja) 2017-10-10 2020-12-17 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2018392717A1 (en) 2017-12-20 2020-07-09 Albert Einstein College Of Medicine Antibodies to Centrin-1, methods of making, and uses thereof
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
WO2019173204A1 (en) * 2018-03-06 2019-09-12 Danisco Us Inc Reduction in acetate production by yeast over-expressing pab1
CN110386985B (zh) * 2018-04-19 2022-09-20 四川大学华西医院 一种肿瘤靶向性促凋亡融合蛋白及其用途
HUE059900T2 (hu) * 2018-05-17 2023-01-28 Twobull Meditherapy P C Eljárások aneurizma vagy rák diagnosztizálására
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3801584B1 (en) 2018-06-04 2023-09-27 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及***
CN109172613B (zh) 2018-08-14 2022-04-22 景岳生物科技(中国)有限公司 含乳杆菌死菌培养物的皮肤外用组合物及其于促进伤口愈合及降低疤痕产生的用途
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MX2021003539A (es) 2018-09-26 2021-05-27 Astellas Pharma Inc Terapia contra el cancer en donde el virus vaccinia oncolitico e inhibidor de punto de control inmunitario se usan en combinacion, y composicion farmaceutica y medicamento de combinacion usado en ella.
AU2019371238A1 (en) * 2018-10-30 2021-06-03 Somalogic Operating Co., Inc. Methods for sample quality assessment
US11655455B2 (en) 2018-11-06 2023-05-23 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
CN109546191B (zh) * 2018-11-07 2021-06-18 大连理工大学 一种混合基质型阴离子膜及其制备方法
CN113891934A (zh) 2018-11-21 2022-01-04 因达普塔治疗公司 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
SG11202107017TA (en) * 2019-01-07 2021-07-29 Kalivir Immunotherapeutics Inc Methods of treating cancer
US11529402B2 (en) 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
WO2020172461A1 (en) * 2019-02-22 2020-08-27 Arizona Board Of Regents On Behalf Of Arizona State University Using tumor-navigating salmonella to modulate tumor metabolism
AU2020229875A1 (en) 2019-02-27 2021-09-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN109810991B (zh) * 2019-03-02 2021-11-12 昆明理工大学 二氢蝶酸合酶基因folP的用途
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4005583A4 (en) * 2019-04-01 2023-04-26 Industry - University Cooperation Foundation Hanyang University ANTI-CANCER AGAINST PEPTIDE-BASED CP2C
CN109957551B (zh) * 2019-04-03 2021-03-23 浙江省医学科学院 表达人β-防御素2的重组痘苗病毒及其应用
US20220241359A1 (en) * 2019-05-15 2022-08-04 Codagenix Inc. Attenuated yellow fever virus and uses thereof for the treatment of cancer
CN114555103A (zh) * 2019-06-03 2022-05-27 伊美诺路克斯国际公司 用于治疗疾病的天花疫苗和干细胞
KR20220054819A (ko) 2019-08-29 2022-05-03 아스테라스 세이야쿠 가부시키가이샤 유전자 변형 암용해 백시니아 바이러스 및 이의 사용 방법
CN110585427B (zh) * 2019-09-06 2023-06-06 刘慧宁 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用
CN110713962B (zh) * 2019-09-06 2022-06-21 南京农业大学 一株高产丙二酰辅酶a的基因工程菌及其构建方法和应用
US11271912B2 (en) * 2019-09-27 2022-03-08 Envistacom, Llc Anonymous communication over virtual, modular, and distributed satellite communications network
CN110551672B (zh) * 2019-09-30 2023-05-23 中国科学院成都生物研究所 高产反式-4-羟基-l-脯氨酸的大肠杆菌菌株及其构建方法
CN110564867B (zh) * 2019-10-10 2022-06-24 扬州大学 一种秦川牛cfl1基因的snp分子标记及其检测方法
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒
EP4073088A1 (en) 2019-12-12 2022-10-19 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
CN111254219B (zh) * 2019-12-27 2023-08-04 上海华盈生物医药科技有限公司 一种用于进行病毒包装效率检测的方法
CN111019877B (zh) * 2019-12-31 2022-04-19 浙江工业大学 一种产l-半胱氨酸的基因工程菌、构建方法及应用
BR112022013521A2 (pt) 2020-01-09 2022-09-13 Pfizer Vírus vaccinia recombinante
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111875699B (zh) * 2020-07-03 2022-07-05 江南大学 一种提高枯草芽孢杆菌卵清蛋白表达量的方法
JP2023533567A (ja) 2020-07-14 2023-08-03 ファイザー・インク 組み換えワクシニアウイルス
CN111705144B (zh) * 2020-07-17 2022-11-18 扬州大学 一个与猪背膘厚关联的znf2基因内sine转座子多态分子标记及其检测方法
CN111913584B (zh) * 2020-08-19 2022-04-01 福州大学 一种基于手势识别的鼠标光标控制方法及***
CN112011555A (zh) * 2020-09-09 2020-12-01 西南大学 一种调控沙门氏菌自裂解的重组基因、重组质粒及其应用
WO2022071966A1 (en) 2020-10-02 2022-04-07 Genelux Corporation Bioreactor production of virus from adherent cells
CN112149041B (zh) * 2020-10-20 2022-12-16 贵州电网有限责任公司 一种基于psd-bpa数据及图形化交互技术的故障分析方法
CN114584999B (zh) * 2020-11-30 2023-08-15 ***通信集团山西有限公司 一种监测***、方法、设备及计算机存储介质
CN113322275A (zh) * 2021-03-24 2021-08-31 中国人民解放军空军军医大学 一种巨噬细胞的CRISPR/Cas9表观编辑***、方法、编辑后的巨噬细胞和应用
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用
CN113363963B (zh) * 2021-05-20 2022-05-20 南昌大学 一种改进麻雀搜索算法优化三相sapf直流侧控制方法
CN113249286B (zh) * 2021-05-25 2023-12-08 洛阳华荣生物技术有限公司 一种构建l-肌氨酸生产菌的方法
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用
CN114395574B (zh) * 2022-01-18 2023-08-11 长沙爱科博生物科技有限公司 一种猪流行性腹泻病毒融合蛋白及其编码基因与应用
US20230233299A1 (en) * 2022-01-27 2023-07-27 EdgeEndo, LLC Dental, endodontic, and periodontic treatment methods and systems
CN114540521B (zh) * 2022-03-23 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 具有降糖降脂功效的植物乳杆菌84-3特异性分子靶标及其检测方法
CN114774468B (zh) * 2022-04-20 2022-12-20 温氏食品集团股份有限公司 一种等位基因分子标记及抗蓝耳病猪群体组建方法
CN115011601B (zh) * 2022-06-27 2023-07-21 山东大学齐鲁医院 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用
US20240033347A1 (en) 2022-07-08 2024-02-01 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
CN117625547A (zh) * 2022-08-25 2024-03-01 广州百吉生物制药有限公司 联合表达gpx4的新一代嵌合抗原受体及其应用
CN116622577B (zh) * 2023-05-26 2023-10-27 山东奈思健康科技有限责任公司 一种促进col1a2和col3a1表达提高胶原蛋白合成的后生元及其制备方法
CN117589991B (zh) * 2024-01-18 2024-03-29 天津云检医学检验所有限公司 一种用于乳腺癌患者her2表达状态鉴定的生物标志物、模型、试剂盒及用途

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US69491A (en) * 1867-10-01 Newark
US29023A (en) * 1860-07-03 Cornelius j
US31643A (en) * 1861-03-05 Bons l
US101480A (en) * 1870-04-05 Improvement in hand seed-planter
US161788A (en) * 1875-04-06 Improvement in bird-cages
US213007A (en) * 1879-03-04 Improvement in safety-pins
US33617A (en) * 1861-10-29 Improvement in grain-separators
US8025A (en) * 1851-04-08 Apparatus eor boltiitg flouk
US54865A (en) * 1866-05-22 Improvement in cow-milkers
US9015A (en) * 1852-06-15 Manufacture of granular fuel from brush-wood and twigs
US59400A (en) * 1866-11-06 Improvement
US83293A (en) * 1868-10-20 Improvement in button-hole cutters
US76622A (en) * 1868-04-14 Bobeet john gaines
US31628A (en) * 1861-03-05 Improvement in sewing-machines
US86906A (en) * 1869-02-16 Improvement in velocipedes
US44384A (en) * 1864-09-27 Improved carpet-fastening
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
US143861A (en) * 1873-10-21 Improvement in picture-frames
US213741A (en) * 1879-04-01 Improvement in portable platforms for fire and other ladders
US160410A (en) * 1875-03-02 Improvement in carbureters or hydrocarbon-diffusers
US228261A (en) * 1880-06-01 lewis
US165465A (en) * 1875-07-13 Improvement in paper-weights
US228330A (en) * 1880-06-01 Advertising checker-board
US160970A (en) * 1875-03-16 Improvement in key-rings
US31681A (en) * 1861-03-12 Puhchifg-machine
JPS5535004Y2 (pt) 1975-07-28 1980-08-19
JPS542336A (en) * 1977-06-06 1979-01-09 Meiji Seika Kaisha Ltd Preventive and remedy for viral diseases
JPS5535004A (en) 1978-09-02 1980-03-11 Wakunaga Yakuhin Kk Cell-immunity activator and its preparation
EP0037441B1 (en) 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
US4442203A (en) * 1981-06-30 1984-04-10 Massachusetts Institute Of Technology Gene amplification assay for detecting tumor promoters
US5378457A (en) * 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4778759A (en) * 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US7045313B1 (en) * 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5221623A (en) * 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
DE3789766T2 (de) 1986-07-22 1994-09-29 Thompson Boyce Plant Res Verwendung von bakteriellen luciferase strukturellen genen zum klonieren und zur steuerung der genexpression in mikroorganismen, sowie zur etikettierung und identifizierung von genetisch gebildeten organismen.
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
ZA891067B (en) * 1988-02-12 1990-04-25 Commw Scient Ind Res Org Pox virus vectors
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
WO1990013658A1 (en) 1989-04-28 1990-11-15 The University Of Alberta Plant hormone regulated expression of genetically engineered gene products in plant cells
AU6877991A (en) 1989-11-28 1991-06-26 Universite Laval A method of inactivating human immunodeficiency virus
ATE260974T1 (de) 1990-06-15 2004-03-15 Scios Inc Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
CA2105277C (en) 1991-03-07 2006-12-12 William I. Cox Genetically engineered vaccine strain
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
ATE247163T1 (de) * 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
US5212082A (en) * 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5718902A (en) 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5762959A (en) * 1992-05-29 1998-06-09 Vivorx, Inc. Microencapsulation of cells
WO1994010302A1 (de) 1992-10-29 1994-05-11 Boehringer Mannheim Gmbh Amplifizierbarer vektor gegen hiv replikation
DE9302762U1 (pt) * 1993-02-25 1993-04-15 Kelm, Eckehart, 8031 Gilching, De
EP1179350A3 (en) * 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US6093700A (en) * 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE69535288T2 (de) 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
JPH07313187A (ja) 1994-05-24 1995-12-05 Sagami Chem Res Center 抗体作製法
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) * 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5840576A (en) 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5853385A (en) 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
JP3907698B2 (ja) * 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
CA2201592A1 (en) 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
US5693533A (en) 1994-12-07 1997-12-02 The Goodwin Institue For Cancer Research Human breast carcinoma cell line capable of production of a spontaneously metastasizing tumor in animals for use in anticancer drug testing
US6503703B1 (en) * 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5646298A (en) * 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5842431A (en) 1997-02-19 1998-12-01 Wu; Chong-Ming Rotating shuttle and presser plate arrangement
US6251384B1 (en) * 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
CA2289283C (en) * 1997-04-28 2009-08-11 Anticancer, Inc. Metastasis models using green fluorescent protein (gfp) as a marker
US6232523B1 (en) * 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6884414B1 (en) * 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6265557B1 (en) 1997-05-09 2001-07-24 Loma Linda University Medical Center ABO histo-blood group O alleles of the baboon
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
JP2001519175A (ja) 1997-10-09 2001-10-23 プロ − バイラス，インコーポレイテッド ウイルスを用いた新生物の処置
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
CN1322137C (zh) 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
US6065557A (en) * 1998-04-01 2000-05-23 Von Keyserling; Peter H. Power assist assembly for wheeled vehicles
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6511967B1 (en) * 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
WO2000073479A1 (en) * 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6627190B2 (en) 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2001005229A1 (en) 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
WO2001012234A1 (en) 1999-08-16 2001-02-22 Uab Research Foundation Gene transfer imaging and uses thereof
CA2381755A1 (en) 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
ES2267561T3 (es) 1999-09-08 2007-03-16 Xenogen Corporation Casetes de expresion de luciferasa y procedimientos de uso.
WO2001020989A1 (en) 1999-09-22 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CN1420783A (zh) * 1999-10-04 2003-05-28 维昂药品公司 用于将效应分子定向递送至肿瘤的组合物及方法
AU7856100A (en) 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
WO2001025399A2 (en) 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
JP2003514024A (ja) 1999-11-12 2003-04-15 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性疾患の治療のためのウイルス
AU2462101A (en) 1999-12-29 2001-07-09 Vanderbilt University Genetic mutation underlying orthostatic intolerance and diagnostic and therapeutic methods relating thereto
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
ES2238421T3 (es) 2000-01-26 2005-09-01 Loma Linda University Metodo para la evaluacion de materiales implantables.
US6448073B1 (en) * 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
CA2403090C (en) 2000-03-17 2014-06-10 Anticancer, Inc. Whole-body optical imaging of gene expression and uses thereof
DE10013511A1 (de) * 2000-03-20 2001-10-11 Brand Gmbh & Co Kg Mehrkanal-Pipettiereinrichtung sowie Pipettenschaft dafür
WO2001075182A1 (fr) 2000-04-04 2001-10-11 Nippon Steel Corporation Profile en acier lamine en forme de h a microstructure uniforme et proprietes mecaniques uniformes ; procede de fabrication
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2002068820A1 (en) * 2001-02-22 2002-09-06 Nanomuscle, Inc. Shape memory alloy actuator with improved temperature control
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1404375A1 (en) * 2001-07-09 2004-04-07 Anticancer, Inc. Imaging infection using fluorescent protein as a marker
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
EP1281772A1 (en) 2001-07-31 2003-02-05 Aladar A. Szalay Light-emitting microorganisms and cells for tumour diagnosis/therapy
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US6840758B2 (en) * 2001-10-26 2005-01-11 Mold-Masters Limited Valve bushing assembly
EP1446012B1 (en) 2001-11-21 2013-07-17 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
CA2467486A1 (en) * 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
EP1470160A2 (en) * 2001-12-05 2004-10-27 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
JP4350519B2 (ja) * 2001-12-31 2009-10-21 アンチキャンサー インコーポレーテッド 細菌による腫瘍治療をモニターするシステム
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
EP1487463A2 (en) * 2002-03-02 2004-12-22 Board Of Regents The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US20030213007A1 (en) 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
AU2003240971A1 (en) 2002-05-29 2003-12-19 Univ California Attenuated listeria spp. and methods for using the same
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20060004191A1 (en) 2002-06-25 2006-01-05 Jhiang Sissy M Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
US7355162B2 (en) * 2002-07-02 2008-04-08 Optitune Plc Optical wavelength measuring device using guiding body and diffractive structure
CA2818693C (en) * 2002-08-12 2016-05-17 Jennerex, Inc. Methods and compositions concerning poxviruses and cancer
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
US7318917B2 (en) 2002-09-06 2008-01-15 Vanderbilt University Rapid assays for neurotransmitter transporters
AU2003279770A1 (en) 2002-10-01 2004-04-23 Novartis Vaccines And Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
AU2003290819A1 (en) 2002-11-12 2004-06-03 Anticancer, Inc. Fluorescence guided cell capture
WO2004098534A2 (en) 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
KR20060002793A (ko) * 2003-03-03 2006-01-09 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｍｄａ-7을 포함하는 방법 및 조성물
US8452294B2 (en) 2003-04-23 2013-05-28 Qualcomm Incorporated In-band ate indicator methods and apparatus
BRPI0411526A (pt) * 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
EP1526185B1 (en) 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
EP1489164A1 (en) 2003-06-18 2004-12-22 Genelux GmbH Recombinant vaccinia viruses with modified F3 genes, uses thereof
ATE445017T1 (de) 2003-08-14 2009-10-15 Genelux Corp Methode zur herstellung eines polypeptides, einer rna oder einer anderen verbindung in tumorgewebe
WO2005057488A2 (en) 2003-12-03 2005-06-23 Anticancer, Inc. Modular system for multi-color, whole body fluorescence imaging
US20080038204A1 (en) 2004-01-26 2008-02-14 Meng Yang Whole Body Imaging Using Portable Observation Systems
WO2005094878A1 (ja) 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
US20060063993A1 (en) * 2004-08-09 2006-03-23 Dejin Yu Method and apparatus for non-invasive measurement of blood analytes
WO2006050274A2 (en) 2004-11-02 2006-05-11 Uab Research Foundation Methods and compositions for cytokine expression and treatment of tumors
US20060193832A1 (en) 2005-02-04 2006-08-31 University Of Iowa Research Foundation Use of the sodium iodine symporter to effect uptake of iodine
JP2006260179A (ja) * 2005-03-17 2006-09-28 Matsushita Electric Ind Co Ltd トラックボール装置
JP5149800B2 (ja) 2005-08-17 2013-02-20 アメリカ合衆国 Ｉｇｆ−ｉｉに特異的に結合するヒトモノクローナル抗体
CA2634591A1 (en) 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
ES2299362B1 (es) 2006-07-11 2009-04-01 Bestile, S.L. Baldosa para revestimiento y pavimentacion.
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2043529A4 (en) 2006-07-12 2016-10-05 Niti Surgical Solutions Ltd COMPRESSION ASSEMBLIES AND APPLICATORS FOR USE WITH THE SAME
DE102006034854A1 (de) 2006-07-25 2008-01-31 Ovd Kinegram Ag Verfahren zur Erzeugen einer Lasermarkierung in einem Sicherheitsdokument sowie derartiges Sicherheitsdokument
US7947255B2 (en) 2006-08-09 2011-05-24 Vanderbilt University Fluorescent substrates for neurotransmitter transporters
US7569396B1 (en) * 2006-09-08 2009-08-04 Purplecow Llc Caffeine detection using internally referenced competitive assays
WO2008043851A1 (en) 2006-10-13 2008-04-17 N.V. Organon A non-homogeneous quencher free assay method for the noradrenaline transporter
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
WO2009126189A1 (en) * 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) * 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2014031693A1 (en) * 2012-08-20 2014-02-27 Genelux Corporation Compositions containing protein polymers and vaccinia virus, and methods of use thereof
WO2014055960A1 (en) * 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US20140271549A1 (en) 2013-03-15 2014-09-18 Aladar A. Szalay Use of Antibiotics to Enhance Treatment With Therapeutic Viruses

Also Published As

Publication number Publication date
US20110300176A1 (en) 2011-12-08
JP2008161196A (ja) 2008-07-17
CA2527225C (en) 2010-05-11
US7588767B2 (en) 2009-09-15
EP2028270B1 (en) 2012-02-15
DE602004018927D1 (de) 2009-02-26
SG179291A1 (en) 2012-04-27
JP4294711B2 (ja) 2009-07-15
US20170095552A1 (en) 2017-04-06
AU2004289953B2 (en) 2008-09-25
RU2376371C2 (ru) 2009-12-20
US20120276010A1 (en) 2012-11-01
US10463730B2 (en) 2019-11-05
AU2008264201A1 (en) 2009-01-29
US7754221B2 (en) 2010-07-13
CA2527225A1 (en) 2005-05-26
JP2007524385A (ja) 2007-08-30
EP1644492A2 (en) 2006-04-12
CN100562570C (zh) 2009-11-25
ATE420160T1 (de) 2009-01-15
US20140294891A1 (en) 2014-10-02
US20050031643A1 (en) 2005-02-10
JP2009201515A (ja) 2009-09-10
JP4961190B2 (ja) 2012-06-27
ATE545699T1 (de) 2012-03-15
EP2028270B9 (en) 2012-04-25
US7588771B2 (en) 2009-09-15
US8323959B2 (en) 2012-12-04
US20100062016A1 (en) 2010-03-11
AU2004289953A1 (en) 2005-05-26
HK1126818A1 (en) 2009-09-11
US8021662B2 (en) 2011-09-20
US20100008946A1 (en) 2010-01-14
JP3934673B1 (ja) 2007-06-20
US9492534B2 (en) 2016-11-15
US20070025981A1 (en) 2007-02-01
MXPA05013879A (es) 2006-06-27
RU2006100679A (ru) 2007-07-27
US20070202572A1 (en) 2007-08-30
US20070212727A1 (en) 2007-09-13
US7662398B2 (en) 2010-02-16
JP2007020586A (ja) 2007-02-01
EP2028270A3 (en) 2009-05-20
EP2028270A2 (en) 2009-02-25
JP5342932B2 (ja) 2013-11-13
US8784836B2 (en) 2014-07-22
HK1084691A1 (en) 2006-08-04
WO2005047458A3 (en) 2005-09-15
AU2008264201B2 (en) 2011-07-28
WO2005047458A2 (en) 2005-05-26
CN1839201A (zh) 2006-09-27
US20060051370A1 (en) 2006-03-09
US8221769B2 (en) 2012-07-17
EP1644492B1 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
BRPI0411526A (pt) vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
ATE386127T1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
HK1082761A1 (en) Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
EA200601946A2 (ru) Антитела, связывающиеся с белками steap-1, и их производные
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
WO2005118864A3 (en) Antibodies and related molecules that bind to psca proteins
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
IL181218A0 (en) Nucleic acids and corresponding 58p1d12 proteins for use in the detection and treatment of cancer
CN104342444A (zh) 一种重组trail蛋白及其制备方法和用途
CN105861551B (zh) 联合表达microRNAs抑制乳腺癌细胞增殖的载体及其构建方法和应用
CN102021173B (zh) 可溶性截短的人trail活性蛋白的制备方法
AU2001269726A1 (en) Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2007013479A3 (en) Genes and polypeptides relating to prostate cancers
Bargahi et al. Effect of shark cartilage derived protein on the NK cells activity
CN109022442B (zh) 一种可有效抑制骨肉瘤生长的生物重组型miR124-3p
CN101386869A (zh) 人甲基鸟嘌呤甲基转移酶基因真核表达质粒及其构建方法与应用
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
CN102657852A (zh) 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用
CN107513107A (zh) 抗肿瘤融合蛋白及其制法和应用
ATE463566T1 (de) Tumor- und seneszenzsmarker

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PEDE-SE QUE O REQUERENTE REAPRESENTE A DITA PETICAO (20070078581), COM MESMO CONTEUDO APRESENTADO ATRAVES DA PETICAO NO 20070078581 DE 13/06/2007.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2337 DE 20/10/2015. ANULACAO DA EXIGENCIA 6.7 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.